190 related articles for article (PubMed ID: 31981828)
1. Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Gouveia F; Bicker J; Santos J; Rocha M; Alves G; Falcão A; Fortuna A
J Pharm Biomed Anal; 2020 Mar; 181():113109. PubMed ID: 31981828
[TBL] [Abstract][Full Text] [Related]
2. Optimization by response surface methodology of a dispersive magnetic solid phase extraction exploiting magnetic graphene nanocomposite coupled with UHPLC-PDA for simultaneous determination of new oral anticoagulants (NAOs) in human plasma.
Ferrone V; Todaro S; Carlucci M; Fontana A; Ventrella A; Carlucci G; Milanetti E
J Pharm Biomed Anal; 2020 Feb; 179():112992. PubMed ID: 31816472
[TBL] [Abstract][Full Text] [Related]
3. Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Wiesen MHJ; Blaich C; Streichert T; Michels G; Müller C
Clin Chem Lab Med; 2017 Aug; 55(9):1349-1359. PubMed ID: 28328524
[TBL] [Abstract][Full Text] [Related]
4. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
[TBL] [Abstract][Full Text] [Related]
5. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Gous T; Couchman L; Patel JP; Paradzai C; Arya R; Flanagan RJ
Ther Drug Monit; 2014 Oct; 36(5):597-605. PubMed ID: 24695356
[TBL] [Abstract][Full Text] [Related]
6. Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application.
Lindahl S; Dyrkorn R; Spigset O; Hegstad S
Ther Drug Monit; 2018 Jun; 40(3):369-376. PubMed ID: 29578938
[TBL] [Abstract][Full Text] [Related]
7. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
[TBL] [Abstract][Full Text] [Related]
8. Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots.
Jhang RS; Lin SY; Peng YF; Chao HC; Tsai IL; Lin YT; Liao HW; Tang SC; Kuo CH; Jeng JS
Anal Chem; 2020 Feb; 92(3):2511-2518. PubMed ID: 31918541
[TBL] [Abstract][Full Text] [Related]
9. Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
Boehr S; Haen E
Ther Drug Monit; 2017 Feb; 39(1):66-76. PubMed ID: 27861316
[TBL] [Abstract][Full Text] [Related]
10. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Zhao Y; Couchman L; Kipper K; Arya R; Patel JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122095. PubMed ID: 32251991
[TBL] [Abstract][Full Text] [Related]
11. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of an ultra-high performance liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of direct oral anticoagulants in human plasma.
Zhang YF; Liu XQ; Wang Y; Xu X; Zhong MK; Zhang P; Ma CL
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122952. PubMed ID: 34598085
[TBL] [Abstract][Full Text] [Related]
14. Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
Kuhn J; Gripp T; Flieder T; Hammerschmidt A; Hendig D; Faust I; Knabbe C; Birschmann I
Clin Chim Acta; 2018 Nov; 486():347-356. PubMed ID: 30114406
[No Abstract] [Full Text] [Related]
15. Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers.
Ćelap I; Margetić S; Brčić M; Mihić R
Biochem Med (Zagreb); 2020 Feb; 30(1):010706. PubMed ID: 32063729
[TBL] [Abstract][Full Text] [Related]
16. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
[TBL] [Abstract][Full Text] [Related]
17. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
Gosselin RC; Adcock DM; Bates SM; Douxfils J; Favaloro EJ; Gouin-Thibault I; Guillermo C; Kawai Y; Lindhoff-Last E; Kitchen S
Thromb Haemost; 2018 Mar; 118(3):437-450. PubMed ID: 29433148
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
19. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
20. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
